What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 2, Pre-Registered Trial).

December 8, 2025BloodOpen Access

Prospective evaluation of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia: A multicenter, randomized controlled, open-lable, phase II Trial

View Full Paper

Ask AI

Bookmark

Authors

YZYu ZhangShihezi University

Discussion

Member takes

Implication

Clinical trial demonstrates improved complete remission rates in relapsed/refractory AML patients receiving venetoclax and CLAG, indicating promising salvage therapy benefits.

Key Points

To evaluate the efficacy and safety of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia.
Conducted as a multicenter, randomized controlled, open-label, phase II trial.
79 patients with relapsed/refractory AML were randomized into experimental (venetoclax + CLAG) and control (CLAG) groups.
Primary endpoint was the rate of composite complete remission (CRc).
75.6% of patients in the experimental group achieved CRc compared to 47.4% in the control group (P=0.010).
Overall response rate was 85.4% in the experimental group versus 52.6% in the control group (P=0.002).
Overall survival at 1 year was 80.8% for the experimental group versus 57.4% for the control group (P=0.028).

Cite This Study

Yu Zhang (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e391 https://doi.org/10.1182/blood-2025-1000

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial demonstrates improved complete remission rates in relapsed/refractory AML patients receiving venetoclax and CLAG, indicating promising salvage therapy benefits.

Prospective evaluation of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia: A multicenter, randomized controlled, open-lable, phase II Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Prospective evaluation of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia: A multicenter, randomized controlled, open-lable, phase II Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider